ArticleRadiation oncology (London, England)2018
Endoscopic submucosal dissection followed by chemoradiotherapy for superficial esophageal cancer: choice of new approach.
Article in Radiation oncology (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 4 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Long-term outcomes of additional surgical versus nonsurgical treatment after non-curative endoscopic resection for T1 superficial esophageal cancer.International journal of surgery (London, England) · 2026Pooled it
- Comparative efficacy and outcomes of different treatments for pathologically high-risk superficial esophageal cancer: a systematic review and network meta-analysis.Frontiers in oncology · 2026Pooled it
- Risk factors of postoperative stricture after endoscopic submucosal dissection for superficial esophageal neoplasms: A meta-analysis.Medicine · 2021Pooled it
- [Surgical treatment of esophageal cancer-Indicators for quality in diagnostics and treatment].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2021Pooled it
- Next step after endoscopic resection for superficial esophageal squamous cell carcinoma: metastatic risk assessment and management of non-curative resection cases.Clinical endoscopy · 2026Review
- Endoscopic Submucosal Dissection and Chemoradiotherapy versus Esophagectomy for T1a-m3 or T1b Esophageal Squamous Cell Carcinoma: A Meta-analysis.Endoscopy international open · 2026Review
- Additional chemoradiotherapy versus esophagectomy for early esophageal cancer: an integrated analysis of reconstructed time-to-event data.Therapeutic advances in gastroenterology · 2026Article
- Outcomes of additional chemotherapy for esophageal squamous cell carcinoma following non-curative endoscopic submucosal dissection.International journal of clinical oncology · 2025Article
- Treatment choices after endoscopic resection for pMM/SM1 esophageal squamous cell cancer: a retrospective study in China.Surgical endoscopy · 2025Article
- Salvage esophagectomy for unresectable locally advanced esophageal squamous cell carcinoma: Significant or not?Annals of gastroenterological surgery · 2025Review
- Current status and perspectives of esophageal cancer: a comprehensive review.Cancer communications (London, England) · 2025Review
- Review
- Additional chemoradiotherapy following endoscopic submucosal dissection in patients with esophageal squamous cell carcinoma: a narrative review.Frontiers in oncology · 2025Review
- Long-Term Follow-Up After Non-Curative Endoscopic Submucosal Dissection for Early Gastrointestinal Cancer-A Retrospective Multicenter Analysis.Journal of clinical medicine · 2024Article
- Unveiling Therapeutic Targets for Esophageal Cancer: A Comprehensive Review.Current oncology (Toronto, Ont.) · 2023Review
- Long-term survival in esophagectomy for early-stage esophageal cancer versus endoscopic resection plus additional chemoradiotherapy: a systematic review and meta-analysis.Journal of thoracic disease · 2023Article
- Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1.Esophagus : official journal of the Japan Esophageal Society · 2023Article
- Clinical models to predict lymph nodes metastasis and distant metastasis in newly diagnosed early esophageal cancer patients: A population-based study.Cancer medicine · 2023Article
- The efficacy of additional surgical resection after endoscopic resection in pT1b esophageal squamous cell carcinoma: A multi-institutional retrospective study in China.Surgical endoscopy · 2023Article
- Additional endoscopic treatments for patients with positive lateral margins after endoscopic resection of early esophageal squamous cell carcinoma.Oncology letters · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe standard treatment for superficial esophageal cancer (SEC) involving muscularis mucosal (T1a-MM) or submucosal (T1b) invasion has been the surgical resection of the esophagus. However, esophagectomy with extended lymph node dissection is highly invasive. Recent reports have shown that endoscopic submucosal dissection (ESD) followed by chemoradiotherapy (CRT) has promising results and might become a new therapeutic approach. This retrospective study aimed to elucidate the efficacy and safety of this new treatment.
methodsPatients with clinical stage T1b tumor without apparent metastasis treated with ESD followed by CRT from 2014 to 2017 (the CRT group) were included. The outcomes on disease-free survival (DFS) of this group were compared with those of consecutive patients in a historical control group who underwent ESD followed by esophagectomy (the esophagectomy group) between 2008 and 2015.
resultsOf 32 patients analyzed, 16 were in the CRT group and 16 with similar stage cancer were in the esophagectomy group. Radiotherapy was completed in all patients, and the incidence of grade ≥ 3 nonhematologic adverse events was 6%. The 2-year overall survival rates were 100%, and locoregional control was achieved in all patients in the CRT group, and the 2-year DFS rates were 88 and 100% for the CRT and esophagectomy groups, respectively, without significant differences.
conclusionsOur data confirmed our new approach as being safe and effective for locoregional control and may provide a nonsurgical treatment option for patients with clinical stage T1b tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.